The MIRA trial: A global, randomized, double-blind, placebo-controlled phase 2 trial to evaluate the efficacy and safety of the IL-17A-and IL-17F-inhibiting nanobody? sonelokimab in patients with active, moderate-to-severe hidradenitis suppurativa
EXPERIMENTAL DERMATOLOGY(2023)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要